Abstract:The epidemiology of IFD following pediatric heart transplantation (pHT) is poorly characterized. We sought to evaluate use of antifungal prophylaxis and describe the epidemiology of IFD in pHT at two large children's hospitals. We performed a retrospective cohort study of pediatric and young adult (≤21 years) patients undergoing heart transplantation at Cincinnati Children's Hospital Medical Center (CCHMC) and Children's Hospital of Philadelphia (CHOP) between 2012 and 2021. We recorded demographic, clinical, medication, and laboratory data for pHT patients through 12 months post-transplant. We identified use of topical (oral nystatin) and systemic antifungal prophylaxes in the peri-transplant period (7 days prior through 14 days following transplant) and analyzed if certain transplant variables were associated with the administration of systemic antifungals during this period using rank sum and chi squared tests. Applying published definitions, we quantified the incidence of proven and probable IFD and explored the characteristics of these cases. A total of 201 patients underwent heart transplant at CCHMC and CHOP. The majority were male (60.2%), White (66.7%), and not Hispanic or Latino (88.1%). Median age at time of transplant was 7.4 years (IQR 0.9-14.2). During the peri-transplant period, 143 (71.1%) patients received oral nystatin and 37 (18.4%) received systemic antifungal prophylaxis, not including PJP prophylaxis. 41 individuals (20.4%) were not on any antifungal prophylaxis throughout this period. Delayed chest closure was significantly associated with the administration of systemic antifungals (p<0.001) while several other variables (age, hospital, immunosuppression medication, ECMO/LVAD pre-transplant) were not. In total, 8 patients (4%) developed proven (n=5) or probable (n=3) IFD. In our cohort, the incidence rate of proven/probable IFD in the first year post-transplant was 44.8 per 1000 patient-years. The characteristics of these cases are shown in Table 1. Time from pHT to IFD ranged from 11 days to 196 days (median time = 25.5 days). All cases of proven IFD occurred within 28 days of transplant. In three cases of proven/probable IFD, patients were receiving a systemic antifungal or PJP prophylaxis in the seven days prior to IFD onset. Two cases met the definition of probable IFD but the infections resolved without directed therapies. Four patients with proven IFD died within 1 year following transplant, although in only 3 cases was IFD a contributing factor. The one-year all-cause mortality rate among pHT patients with proven/probable IFD (50%) was higher than that in pHT patients without IFD (10.3%; Fisher's exact p=0.008). Over a 10-year period at CCHMC and CHOP, 4% of pHT patients developed proven or probable IFD within one-year post-transplant. All proven IFD cases occurred within a month of transplant while probable cases occurred more than 100 days post-transplant. Delayed chest closure was significantly associated with the administration of systemic antifungal prophylaxis. Patients with proven IFD had poor outcomes despite receipt of appropriate antifungal treatment. Given the low incidence of IFD at these two centers, we were unable to evaluate risk factors for IFD in this population and so larger studies would be needed. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD. Table 1 Characteristics of patient with proven or probable invasive fungal disease Abbreviations: IFD, invasive fungal disease; NOS, not otherwise specified. Seen on microscopic examination of peritoneal fluid but did not grow on culture. Diagnosed on respiratory culture, with positive bronchoalveolar lavage cytology and imaging concerning for pulmonary fungal disease. Positive antigen testing in serum in the setting of pulmonary nodules. Positive PCR on sputum specimen in patient with pulmonary infiltrates. Patient died within one year of transplant but unrelated to IFD.

Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective

Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps

Pharmacokinetic considerations in treating invasive pediatric fungal infections

A novel approach to reducing hepatotoxicity related to fungal prophylaxis in pediatric lung transplant recipients

Approach to diagnostic evaluation and prevention of invasive fungal disease in patients prior to allogeneic hematopoietic stem cell transplant

Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients

Invasive fungal infections in liver transplantation.

Invasive fungal infections in critically ill children: epidemiology, risk factors and antifungal drugs

Antifungal drugs: What brings the future?

An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old

A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation

Invasive Fungal Disease in Pediatric Heart Transplant Recipients

Drug repurposing strategies in the development of potential antifungal agents

New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections

DIAGNOSIS AND PREVENTION OF INVASIVE FUNGAL INFECTIONS IN THE IMMUNOCOMPROMISED HOST

Antifungal Prophylaxis Utilization and the Associated Clinical Outcomes Among Pediatric Patients with Hematological Malignancies or Undergoing Hematopoietic Stem Cell Transplantation

Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients

A Systematic Review on Fluconazole and Itraconazole As Antifungal Prophylaxis of Invasive Fungal Infection after Transplantation

Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies

Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations